UY31053A1 - Derivados heterociclicos, procesos para su produccion, medicamentos que comprende estos compuestos y su uso - Google Patents

Derivados heterociclicos, procesos para su produccion, medicamentos que comprende estos compuestos y su uso

Info

Publication number
UY31053A1
UY31053A1 UY31053A UY31053A UY31053A1 UY 31053 A1 UY31053 A1 UY 31053A1 UY 31053 A UY31053 A UY 31053A UY 31053 A UY31053 A UY 31053A UY 31053 A1 UY31053 A1 UY 31053A1
Authority
UY
Uruguay
Prior art keywords
compounds
processes
production
derivatives
heterociclical
Prior art date
Application number
UY31053A
Other languages
English (en)
Inventor
Andreas Herling
Hans Matter
Marc Dietrich Voss
Stefanie Keil
Gerhard Zoller
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of UY31053A1 publication Critical patent/UY31053A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Derivados heterocíclicos, procesos para su produccion, medicamentos que comprende estos compuestos y su uso. La invencion se refiere a compuestos de formula I en la que los radicales R1, M, A, B, D, L y R son cada uno como se definio anteriormente, y a las sales fisiologicamente compatibles. Los compuestos resultan adecuados, por ejemplo, para el tratamiento del síndrome matabolico, la resistencia a la insulina, la obesidad y la diabetes.
UY31053A 2007-04-27 2008-04-25 Derivados heterociclicos, procesos para su produccion, medicamentos que comprende estos compuestos y su uso UY31053A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07008646 2007-04-27

Publications (1)

Publication Number Publication Date
UY31053A1 true UY31053A1 (es) 2008-11-28

Family

ID=38473076

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31053A UY31053A1 (es) 2007-04-27 2008-04-25 Derivados heterociclicos, procesos para su produccion, medicamentos que comprende estos compuestos y su uso

Country Status (17)

Country Link
US (2) US8003677B2 (es)
EP (1) EP2152711B1 (es)
JP (1) JP2010524987A (es)
KR (1) KR20100015975A (es)
CN (1) CN101663306A (es)
AR (1) AR066290A1 (es)
AT (1) ATE489389T1 (es)
AU (1) AU2008248996A1 (es)
BR (1) BRPI0810858A2 (es)
CA (1) CA2685543A1 (es)
CL (1) CL2008001215A1 (es)
DE (1) DE502008001903D1 (es)
IL (1) IL201764A0 (es)
MX (1) MX2009011112A (es)
TW (1) TW200911809A (es)
UY (1) UY31053A1 (es)
WO (1) WO2008135141A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010028761A1 (de) * 2008-09-09 2010-03-18 Sanofi-Aventis 2-heteroaryl-pyrrolo[3, 4-c]pyrrol-derivate und ihre verwendung als scd inhibitoren
US20120010186A1 (en) * 2009-03-23 2012-01-12 Merck Frosst Canada Ltd. Heterocyclic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
US8835427B2 (en) 2010-01-07 2014-09-16 E I Du Pont De Nemours And Company Fungicidal heterocyclic compounds
CN102260265B (zh) * 2010-05-24 2015-09-02 上海阳帆医药科技有限公司 六氢吡咯[3,4-b]吡咯衍生物、其制备方法及其用途
JP2013538215A (ja) 2010-08-31 2013-10-10 エスエヌユー アールアンドディービー ファウンデーション ＰＰＡＲδアゴニストの胎児再プログラミング用途
US8501768B2 (en) * 2011-05-17 2013-08-06 Hoffmann-La Roche Inc. Hexahydrocyclopentapyrrolone, hexahydropyrrolopyrrolone, octahydropyrrolopyridinone and octahydropyridinone compounds
CA2850836A1 (en) 2011-10-15 2013-04-18 Genentech, Inc. Methods of using scd1 antagonists
EA201492223A1 (ru) 2012-06-13 2015-03-31 Ф. Хоффманн-Ля Рош Аг Новые диазаспироциклоалканы и азаспироциклоалканы
EP2900669B1 (en) 2012-09-25 2019-09-04 F.Hoffmann-La Roche Ag Hexahydropyrrolo[3,4-c]pyrrole derivatives and related compounds as autotaxin (atx) inhibitors and as inhibitors of the lysophosphatidic acid (lpa) production for treating e.g. renal diseases
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
KR20160087900A (ko) 2013-11-26 2016-07-22 에프. 호프만-라 로슈 아게 신규한 옥타하이드로-사이클로부타[1,2-c；3,4-c'']다이피롤-2-일
UA119347C2 (uk) 2014-03-26 2019-06-10 Ф. Хоффманн-Ля Рош Аг Конденсовані [1,4]діазепінові сполуки як інгібітори продукції аутотаксину (atх) та лізофосфатидилової кислоти (lpa)
CN106103446B (zh) 2014-03-26 2019-07-30 豪夫迈·罗氏有限公司 作为自分泌运动因子(atx)和溶血磷脂酸(lpa)生产抑制剂的二环化合物
WO2016046837A1 (en) 2014-09-22 2016-03-31 Cadila Healthcare Limited An improved process for preparation of pyrrolo[3,4- c] pyrrole compounds and intermediates thereof
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
AU2016316717B2 (en) 2015-09-04 2021-02-18 F. Hoffmann-La Roche Ag Phenoxymethyl derivatives
EP3353180B1 (en) 2015-09-24 2022-03-16 F. Hoffmann-La Roche AG Bicyclic compounds as atx inhibitors
KR20180053408A (ko) 2015-09-24 2018-05-21 에프. 호프만-라 로슈 아게 이중 오토탁신(atx)/탄산 무수화효소(ca) 억제제로서의 신규한 이환형 화합물
WO2017050792A1 (en) * 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag Bicyclic compounds as atx inhibitors
MX2018001430A (es) * 2015-09-24 2018-04-20 Hoffmann La Roche Nuevos compuestos biciclicos como inhibidores duales de autotaxina (atx)/anhidrasa carbonica (ca).
CN108299437B (zh) * 2017-01-13 2022-07-08 广东东阳光药业有限公司 八氢吡咯并[3,4-c]吡咯衍生物及其用途
RU2019132254A (ru) 2017-03-16 2021-04-16 Ф. Хоффманн-Ля Рош Аг Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca
CN110382484B (zh) 2017-03-16 2022-12-06 豪夫迈·罗氏有限公司 新的作为atx抑制剂的二环化合物
NZ763766A (en) 2017-03-20 2023-07-28 Novo Nordisk Healthcare Ag Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators
BR112021005188A2 (pt) 2018-09-19 2021-06-08 Forma Therapeutics, Inc. tratamento de anemia falciforme com um composto de ativação de piruvato cinase r
EP3852791B1 (en) 2018-09-19 2024-07-03 Novo Nordisk Health Care AG Activating pyruvate kinase r
WO2024112764A1 (en) 2022-11-21 2024-05-30 Novo Nordisk Health Care Ag Synthesis of pyrrolo[3,4-c]pyrroles

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005329423A1 (en) * 2004-09-20 2006-09-28 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
CN101083982A (zh) * 2004-09-20 2007-12-05 泽农医药公司 用于治疗硬脂酰CoA去饱和酶介导的疾病的杂环衍生物

Also Published As

Publication number Publication date
US20110245263A1 (en) 2011-10-06
CL2008001215A1 (es) 2008-09-22
AU2008248996A1 (en) 2008-11-13
MX2009011112A (es) 2009-10-28
CN101663306A (zh) 2010-03-03
ATE489389T1 (de) 2010-12-15
BRPI0810858A2 (pt) 2014-10-29
KR20100015975A (ko) 2010-02-12
DE502008001903D1 (de) 2011-01-05
US20100144594A1 (en) 2010-06-10
TW200911809A (en) 2009-03-16
CA2685543A1 (en) 2008-11-13
WO2008135141A1 (de) 2008-11-13
EP2152711A1 (de) 2010-02-17
US8003677B2 (en) 2011-08-23
EP2152711B1 (de) 2010-11-24
IL201764A0 (en) 2010-06-16
AR066290A1 (es) 2009-08-12
JP2010524987A (ja) 2010-07-22

Similar Documents

Publication Publication Date Title
UY31053A1 (es) Derivados heterociclicos, procesos para su produccion, medicamentos que comprende estos compuestos y su uso
UY32094A (es) Derivados heterocíclicos, procesos para su preparación, medicamentos que comprenden dichos compuestos y su uso.
CU20120099A7 (es) Derivados de pirazina y su uso en el tratamiento de trastornos neurológicos
UY31351A1 (es) (ciclopropilfenil)feniloxamidas, procedimiento para su preparación y su uso como medicamentos
UY31968A (es) Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
CY1116424T1 (el) Παραγωγο αδενινης ως αναστολεας ρι3κ
UY32799A (es) Derivados de oxazina y su uso en el tratamiento de trastornos neurológicos
CR20140161A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
PE20180318A1 (es) Procedimiento para preparar isoquinolinonas y formas solidas de isoquinolinonas
CU20140048A7 (es) Novedosos derivados de purina útiles en el tratamiento del cáncer y trastornos neurodegenerativos
ECSP16078782A (es) Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
CR10148A (es) Derivados de las benzamidas y heteroarenos
CO6781507A2 (es) Novedosos derivados heterociclicos
CU20110088A7 (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), producción y uso de los mismos como productos medicinales
ECSP12011830A (es) Nuevos compuestos.
ECSP11011079A (es) Nuevos compuestos de hidroxiareno.
UY31651A1 (es) Nuevos derivados de fluoroglicósidos aromáticos, medicamentos que comprenden estos compuestos y uso de los mismos.
UY31645A1 (es) Nuevas imidazolidinas fenil-sustituidas, procedimiento para su preparación, medicamentos que conprenden dichos compuestos y su uso.
UY28726A1 (es) N-ciclohexilimidazolinonas sustituidas.procedimientos para su preparación y su uso como medicamentos.
UY31644A1 (es) Imidazolina -2,4-dionas sustituidas, procesos para su preparación, medicamentos que comprenden estos compuestos y uso de los mismos.
UY32240A (es) Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones.
DOP2014000114A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
CR11057A (es) Nuevos compuestos heterociclicos nitrogenados, su preparacion y su utilizacion como medicamentos antibacterianos
UY31646A1 (es) Uso de fenilimidazolidinas sustituidas para producir medicamentos para el tratamiento del síndrome metabólico
CO6460762A2 (es) 5-alquinil-piridinas

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20130408